# Novo Nordisk announced stronger-than-expected first-quarter earnings, yet faces mounting challenges.

*biotech · news · 2026-05-06 · Devdiscourse*

## Key points

- Novo Nordisk reported a first-quarter operating profit of 32.86 billion Danish crowns, beating forecasts.
- Adjusted sales and profit forecasts for Novo Nordisk in 2024 have been upgraded slightly.
- Eli Lilly received FDA approval for its obesity drug Foundayo, intensifying competition with Novo Nordisk.
- Novo Nordisk suffered a significant share price drop after recent drug price cuts and weaker trial results.

**Companies:** Novo Nordisk, Eli Lilly
**Countries:** Denmark, United States

[Read the full story on Devdiscourse](https://www.devdiscourse.com/article/business/3898193-novo-nordisks-weighty-battle-navigating-the-obesity-drug-war)

---

Canonical: https://newsio.io/n/716d4485-8c73-41c0-b728-de7113e43422/novo-nordisk-announced-stronger-than-expected-first-quarter-earnings-yet-faces-m
Summarized by Newsio from Devdiscourse. https://newsio.io/how-it-works